PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene ...

Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market ...

Next-gen benchtop system enables engineers to move from Gerber file to fully assembled, production-grade circuit boards within a single integrated platform Expected to become commercially available ...

Draft amendments to the Medical Device Rules seek to reduce manufacturing licence timelines for Class B, C and D devices to improve regulatory efficiency and ease of doing business ...

(MENAFN- EIN Presswire) EINPresswire/ -- Electroninks, the leader in metal complex inks for additive manufacturing and advanced semiconductor packaging, today announced the commercial launch timeline ...